Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

GLP-1 medications have become popular for weight loss, and for good reason—they can help regulate appetite and support weight ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

as prior studies have reported GLP-1 receptor agonist discontinuation rates of up to 81%, Emanuel's group wrote. They added that the links between weight loss and discontinuation and between ...

GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza, Wegovy started as a way to treat diabetes but have since become popular for weight loss.

GLP-1 receptor agonists (like Wegovy and Mounjaro) have gained global attention for their ability to help people shed significant weight. These weight loss medications, administered via injections ...

"The body of evidence for the GLP-1 drug class shows that up to 40% of total weight loss in GLP-1 patients is lean body mass including skeletal muscle mass, 1" said Mitchell Glass, M.D., President ...